Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for
patients with relapsed or relapsed/refractory multiple myeloma.